Epidemiology, treatment and health care resource use of patients with severe asthma in Germany – a retrospective claims data analysis
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Asthma causes various clinical symptoms, including unpredictable severe exacerbations, and even though most patients can achieve a reasonable disease control due to adequate treatment, some patients do not. This study seeks to describe healthcare resource utilization (HCRU) and treatment of asthma and severe asthma patients in Germany. METHOD: A retrospective claims data analysis has been conducted on adult asthma patients and a subset of patients with severe asthma, identified during July 2017 - June 2018. A proxy was used to identify severe asthma patients based on therapy options recommended within the German treatment guideline for treating these patients. These include (i) biologics, (ii) medium/high-dose inhaled corticosteroids (ICS) in conjunction with LABA/montelukast and antibiotics/oral corticosteroids (OCS), and (iii) long-term OCS therapy. HCRU and treatment of patients were observed during a 1-year follow-up period (July 2018 - June 2019). RESULTS: The study included 388 932 adult asthma patients (prevalence: 7.90%), with 2.51%-12.88% affected by severe asthma (depending on the definition). 22.60% of all asthma patients experienced hospitalizations (severe asthma: 36.11%). Furthermore, 13.59% received OCS (severe asthma: 39.91%), but only 0.18% (severe asthma: 1.25%) received biologics. Only 23.95% (severe asthma: 41.17%) visited a pulmonologist. CONCLUSIONS: A considerable proportion of severe asthma patients receive long-term OCS therapy. However, less than 50% have seen a pulmonologist who would typically seek a change in treatment to avoid the long-term consequences of OCS. To optimize the treatment of severe asthma in Germany, better referral of these patients to specialists is needed and considering potential treatment alternatives.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Epidemiology, treatment and health care resource use of patients with severe asthma in Germany – a retrospective claims data analysis
- Date Crossref
- 01/12/2022
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Wismar University of Applied Sciences pays non établi dans la noticeUniversité ou école supérieure
-
GlaxoSmithKline (Germany) pays non établi dans la noticeEntreprise
-
AOK pays non établi dans la noticeÉtablissement de santé
-
Praxis für Hämatologie und Onkologie pays non établi dans la noticeÉtablissement de santé
-
IPAM pays non établi dans la noticeInstitution
-
GlaxoSmithKline GmbH & Co. KG pays non établi dans la noticeEntreprise
-
Schwerpunktpraxis Colonnaden pays non établi dans la noticeInstitution
Wismar University of Applied Sciences, GlaxoSmithKline (Germany) et AOK, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.